Peptic ulcers may be treated with omeprazole. Infection with Helicobacter pylori can be treated by taking omeprazole, amoxicillin, and clarithromycin together for 7–14 days.[26] Amoxicillin may be replaced with metronidazole in patients who are allergic to penicillin.[27]
Concern has been expressed regarding vitamin B12[33] and ironmalabsorption,[34] but effects seem to be insignificant, especially when supplement therapy is provided.[35]
Since their introduction, proton-pump inhibitors (PPIs, especially omeprazole) have also been associated with several cases of acute interstitial nephritis,[36] an inflammation of the kidneys that often occurs as an adverse drug reaction.
Long-term use
Long-term use of PPIs is strongly associated with the development of benign polyps from fundic glands (which is distinct from fundic gland polyposis); these polyps do not cause cancer and resolve when PPIs are discontinued. No association is seen between PPI use and cancer, but use of PPIs may mask gastric cancers or other serious gastric problems.[37]
There is a possible association between long-term use and dementia which requires further study to confirm.[38]
The safety of using omeprazole has not been established in pregnant or breastfeeding women.[16] Epidemiological data do not show an increased risk of major birth defects after maternal use of omeprazole during pregnancy.[40]
Interactions
Omeprazol Actavis 20 mg, bottle and pills in Sweden
Important drug interactions are rare.[41][42] However, the most significant major drug interaction concern is the decreased activation of clopidogrel when taken together with omeprazole.[43] Although still controversial,[44] this may increase the risk of stroke or heart attack in people taking clopidogrel to prevent these events.
This interaction is possible because omeprazole is an inhibitor of the enzymes CYP2C19 and CYP3A4.[45]Clopidogrel is an inactive prodrug that partially depends on CYP2C19 for conversion to its active form. Inhibition of CYP2C19 may block the activation of clopidogrel, which could reduce its effects.[46][47]
Almost all benzodiazepines are metabolised by the CYP3A4 and CYP2D6 pathways, and inhibition of these enzymes results in a higher area under the curve (i.e., the total effect over time of a given dose). Other examples of drugs dependent on CYP3A4 for their metabolism are escitalopram,[48]warfarin,[49]oxycodone, tramadol, and oxymorphone. The concentrations of these drugs may increase if they are used concomitantly with omeprazole.[50]
Omeprazole is also a competitive inhibitor of p-glycoprotein, as are other PPIs.[51]
Drugs that depend on an acidic stomach environment (such as ketoconazole or atazanavir) may be poorly absorbed, whereas acid-labile antibiotics (such as erythromycin which is a very strong CYP3A4 inhibitor) may be absorbed to a greater extent than normal due to the more alkaline environment of the stomach.[50]
Omeprazole irreversibly blocks the enzyme system on parietal cells that is needed for the secretion of gastric acid. It is a specific H+/K+ATPase inhibitor. This is the enzyme needed for the final step in the secretion of gastric acid.[53]
Pharmacokinetics
The absorption of omeprazole takes place in the small intestine and is usually completed within three to six hours. The systemic bioavailability of omeprazole after repeated doses is about 60%.[54] Omeprazole has a volume of distribution of 0.4 L/kg. It has high plasma protein binding of 95%.[55]
Omeprazole is completely metabolized by the cytochrome P450 system, mainly in the liver, by CYP2C19 and CYP3A4isoenzymes.[16] Identified metabolites are the sulfone, the sulfide, and hydroxy-omeprazole. About 77% of an orally given dose is excreted as metabolites in the urine, and the remainder is found in the feces, primarily originating from bile secretion.[56] Omeprazole has a half life of 0.5 to 1 hour.[56]
Bioactivation
As with all structually-similar benzimidazole proton pump inhibitors, omeprazole is a prodrug. A basic molecule, it accumulates in the acidic canaliculi of parietal cells in a protonated form where the S=O group becomes S-OH, which in turn is interconvertible with an achiral, reactive sulfonamide form. The sulfonamide form is able to attach onto the cysteine residue on the H+/K+-ATPase, thereby irreversibly inhibiting it.[57]
Chirality
The two different chiralities of omeprazole are both metabolized into inactive products by cytochrome P450 enzymes, but each chirality are differently inactivated by specific isozymes. Compared to the (R)-enantiomer, the (S)-enantiomer is relatively more resistant to metabolism, especially metabolism by CYP2C19[58] (if it's processed by CYP2C19 at all).[59] As a result, among people with a more active version of CYP2C19 ("extensive metabolizers"), the (R) half of a dose of omeprazole is likely to perform more poorly. Conversely, among those with a less active version of CYP2C19 ("poor metabolizers"), more the (R) half is expected to survive metabolism and end up useful. The proportion of the poor metabolizer phenotype varies widely between populations, from 2.0 to 2.5% in African Americans and white Americans to >20% in Asians. Several pharmacogenomics studies have suggested that PPI treatment should be tailored according to CYP2C19 metabolism status.[60]
Omeprazole is a selective and irreversible proton pump inhibitor. It suppresses stomach acid secretion by specific inhibition of the H+/K+-ATPase system found at the secretory surface of gastric parietal cells. Because this enzyme system is regarded as the acid (proton, or H+) pump within the gastric mucosa, omeprazole inhibits the final step of acid production.[53]
Omeprazole also inhibits both basal and stimulated acid secretion irrespective of the stimulus[56] as it blocks the last step in acid secretion.[56] The drug binds non-competitively so it has a dose-dependent effect.[55]
The inhibitory effect of omeprazole occurs within one hour after oral administration. The maximum effect occurs within two hours. The duration of inhibition is up to 72 hours. When omeprazole is stopped, baseline stomach acid secretory activity returns after three to five days. The inhibitory effect of omeprazole on acid secretion will plateau after four days of repeated daily dosing.[62]
Omeprazole is only effective on active H+/K+-ATPase pumps. These pumps are stimulated in the presence of food to aid in digestion.[63]
Chemistry
Omeprazole contains a tricoordinated sulfinyl sulfur in a pyramidal structure and therefore can exist as either the (S)- or (R)-enantiomers. Omeprazole is a racemate, an equal mixture of the two.[57]
Measurement in body fluids
Omeprazole may be quantified in plasma or serum to monitor therapy or to confirm a diagnosis of poisoning in hospitalized patients. Plasma omeprazole concentrations are usually in a range of 0.2–1.2 mg/L in persons receiving the drug therapeutically by the oral route and 1–6 mg/L in people with acute overdose. Enantiomeric chromatographic methods are available to distinguish esomeprazole from racemic omeprazole.[64]
Omeprazole was first made in 1979 by Swedish AB Hässle, part of Astra AB. It was the first of the proton pump inhibitors (PPI).[65][66]Astra AB, now AstraZeneca, launched it as an ulcer medicine under the name Losec in Sweden. It was first sold in the United States in 1989 under the brand name Losec. In 1990, at the request of the US Food and Drug Administration, the brand name Losec was changed to Prilosec to avoid confusion with the diuretic Lasix (furosemide).[67] The new name led to confusion between omeprazole (Prilosec) and fluoxetine (Prozac), an antidepressant.[67] Prilosec is owned by Procter & Gamble in alliance with AstraZeneca[68] and the product is designed to address frequent heartburn, which can be triggered by various factors such as certain foods, stress, and smoking.
Prilosec was first introduced in 1989 as a prescription medication approved by the FDA for the treatment of severe heartburn[69]. In 2003, Prilosec OTC was launched as the first over-the-counter option for managing frequent heartburn[70]. It is known for its advertising campaign featuring Larry the Cable Guy as the spokesperson for the brand, during the 2010s, emphasizing the concept of "Zero Heartburn."[71]
Society and culture
Economics
When Prilosec's US patent expired in April 2001, AstraZeneca introduced esomeprazole (Nexium) as a patented replacement drug.[72] Many companies introduced generics as AstraZeneca's patents expired worldwide, which are available under many brand names.
Omeprazole was a subject of a patent litigation in the U.S.[73] The invention involved application of two different coatings to a drug in pill form to ensure that the omeprazole did not disintegrate before reaching its intended site of action in stomach. Although the solution by means of two coatings was obvious, the patent was found valid, because the source of the problem was non-obvious and was discovered by the patentee.[74]
In September 2023, AstraZeneca announced it would pay $425 million to settle product liability litigations against Prilosec in the United States.[75]
Brand names
Brand names include Losec, Prilosec, Zegerid, Miracid, and Omez.[2][1]
Veterinary uses
In February 2025, the Committee for Veterinary Medicinal Products of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the veterinary medicinal product Omeprazole TriviumVet, gastro-resistant capsule, hard, intended for dogs.[76] The applicant for this veterinary medicinal product is TriviumVet DAC.[76] Omeprazole TriviumVet was authorized for veterinary use in the European Union in April 2025.[7]
References
^ abcdefghijk"Omeprazole". The American Society of Health-System Pharmacists. Archived from the original on 19 February 2011. Retrieved 21 October 2018.
^ abcVallerand AH, Sanoski CA, Deglin JH (2015). Davis's Drug Guide for Nurses (14th ed.). F.A. Davis Company. pp. 924–925. ISBN978-0-8036-4085-6. OCLC881473728.
^World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.
^McTavish D, Buckley MM, Heel RC (July 1991). "Omeprazole. An updated review of its pharmacology and therapeutic use in acid-related disorders". Drugs. 42 (1): 138–170. doi:10.2165/00003495-199142010-00008. PMID1718683.
^Sarzynski E, Puttarajappa C, Xie Y, Grover M, Laird-Fick H (August 2011). "Association between proton pump inhibitor use and anemia: a retrospective cohort study". Digestive Diseases and Sciences. 56 (8): 2349–2353. doi:10.1007/s10620-011-1589-y. PMID21318590. S2CID33574008.
^McColl KE (March 2009). "Effect of proton pump inhibitors on vitamins and iron". The American Journal of Gastroenterology. 104 (Suppl 2): S5 –S9. doi:10.1038/ajg.2009.45. PMID19262546. S2CID31455416.
^Focks JJ, Brouwer MA, van Oijen MG, Lanas A, Bhatt DL, Verheugt FW (April 2013). "Concomitant use of clopidogrel and proton pump inhibitors: impact on platelet function and clinical outcome- a systematic review". Heart. 99 (8): 520–527. doi:10.1136/heartjnl-2012-302371. PMID22851683. S2CID23689175.
^Cederberg C, Andersson T, Skånberg I (January 1989). "Omeprazole: pharmacokinetics and metabolism in man". Scandinavian Journal of Gastroenterology. Supplement. 166 (sup166): 33–40. doi:10.3109/00365528909091241. PMID2690330.
^ abClissold SP, Campoli-Richards DM (July 1986). "Omeprazole. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peptic ulcer disease and Zollinger-Ellison syndrome". Drugs. 32 (1): 15–47. doi:10.2165/00003495-198632010-00002. PMID3527658.
^ abcd"Omeprazole". www.drugbank.ca. Archived from the original on 30 January 2019. Retrieved 29 January 2019.
^Shiohira H, Yasui-Furukori N, Yamada S, Tateishi T, Akamine Y, Uno T (August 2012). "Hydroxylation of R(+)- and S(-)-omeprazole after racemic dosing are different among the CYP2C19 genotypes". Pharmaceutical Research. 29 (8): 2310–2316. doi:10.1007/s11095-012-0757-x. PMID22549736.
^Baselt RC, Disposition of Toxic Drugs and Chemicals in Man, 8th edition, Biomedical Publications, Foster City, CA, 2008, pp. 1146–7. ISBN978-0-9626523-7-0.
